Autumn Statement 2023 analysis

Martin Turner headshot

The Chancellor yesterday delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. In this blog, Dr Martin Turner, Head of Policy and Public Affairs at BIA shares his reflections on key announcements.

The Chancellor yesterday delivered a comprehensive package of investment and support for the UK life sciences industry in his Autumn Statement. He said he is “incredibly proud of our life sciences industry” and highlighted that British-discovered vaccines and treatments saved more lives across the world during the pandemic than those from any other country.

Key announcements were:

  • £520 million in capital grants available for medicine manufacturing that will enable the UK to compete to be the home for next-generation technologies like mRNA and CRISPR;
  • Further pension reforms to unlock investment, £50 million for the Future Fund: Breakthrough, and a new VC Fellowship scheme to train the next generation of investors;
  • Decreasing the threshold for R&D intensive SME tax credit from 40% to 30% and introducing flexibility. There will also be no restrictions claims for grant-funded R&D projects;
  • Accepting the recommendations of the spin-out review to increase the pace, quality and success of companies coming from UK universities;
  • New investment zones, demonstrating the importance of life sciences to the economy across the country.

All the Autumn Statement documents and the Chancellor’s speech can be found on the HM Treasury website.

BIA’s CEO, Steve Bates, has welcomed the announcements. Join our webinar to hear more on Friday. 

R&D tax relief reforms 

There will be more flexibility for R&D-intensive SMEs through the special scheme previously announced in March whereby loss-making SMEs receive 27p for every £1 they invest. The Autumn Statement reduced the R&D intensity threshold from 40%, as first announced in March, down to 30% from April 2024 onwards. Companies will also remain eligible to claim through the scheme if their R&D intensity drops below the threshold for a single year. This is welcome flexibility that BIA has called for, as one-off large non-R&D costs could inadvertently hit life science companies.

The Treasury also confirmed that it will go ahead with a new R&D tax relief scheme, which will run alongside the R&D-intensive scheme, and end its long-running review of the regime (although more anti-fraud measures may still be brought in). Read this blog for an explainer. The rate of benefit under the new scheme will be 20% whist the notional tax rate applied to loss-makers in the merged scheme will be the small profits rate of 19%, rather than the 25% main rate set in the current RDEC. This will result in an after-tax cash benefit for loss-making companies of 16.2p for each £1 invested in-house and 10.5p for contracted-out R&D. Restrictions on claims for subsidised R&D (i.e. grant-funded projects) will also be removed for all schemes in the future. This is really welcome as it’ll make Innovate UK grants more valuable.

We expect the Autumn Finance Bill 2023 in the next week or so to legislate for these changes and provide further clarity on the new regime, but it is the HMRC guidance we urgently need and have been waiting for. We are contacting HMRC directly and pressing for this to be published so that life science SMEs can forecast their finances.

A short paper was published alongside the Autumn Statement setting out more detail on these reforms.

Other tax measures

A major plank of the Chancellor’s growth strategy was making permanent full expensing, which was previously a temporary measure running until the end of March 2026. This has been called for by many trade associations, including BIA and ABPI, and supported by the Labour Party. 

Companies can claim 100% capital allowances on qualifying plant and machinery investments, and full expensing allows them to write off the cost of investment in one go. Under full expensing, for every pound a company invests, their taxes are cut by up to 25p. It largely benefits profit-making companies. It will make the UK a more competitive location for medicines manufacturing and new R&D facilities, which will strengthen the UK ecosystem.

The Government will also legislate in the Autumn Finance Bill 2023 to extend the existing sunset clauses for the EIS and VCT from 6 April 2025 to 6 April 2035. It also published an analysis of the effectiveness of these schemes. Overall, the findings from this research suggested EIS was supporting companies subject to the relevant market failures and the scheme had a significant positive impact on the situation of these companies.

Manufacturing and investment across the UK

The government will invest £520 million to secure life sciences manufacturing between 2025 and 2030. This is a significant and extremely welcome expansion of similar schemes run since 2021.

Through the Medicines Manufacturing Industry Partnership (of BIA, ABPI, Innovate UK and the Office for Life Sciences), industry has called for an expansion of a capital grants programme that covers 10-15% of new manufacturing facilities. This funding will make the UK more internationally competitive to win a share of the global next-generation medicine manufacturing market in technologies like mRNA and CRISPR.

The Chancellor confirmed the Investment Zones programme in England will be extended from five to 10 years, with the envelope of government funding and tax reliefs on offer now doubled to £160 million. West Yorkshire will host one of 12 Investment Zones across the UK. It’s based around the region’s universities in Leeds, Bradford and Huddersfield and the cluster of life sciences businesses thriving in the area. The new Liverpool City zone will focus on life science. There was also a promise to review planning rules to enable the building of more factories and facilities, something which Labour have committed to reforming, with Rachel Reeves saying: “we will fast-track… our life sciences… to grow our economy and provide good jobs in every part of our country”.

The Lord Harrington’s Review looking at how the UK can better attract foreign direct investment into key growth sectors was also published. There will be a new concierge service for large foreign investors. BIA fed into this in meetings with the minister, we’ll analyse its recommendations shortly.  

Unlocking pension funds

There is a great deal of momentum following the Mansion House Compact, including the launch of the Venture Capital (VC) Investment Compact and the Mansion House Pension Summit bringing together pension funds, trustees and private market investors for the first time.

A large package of reforms was published alongside the Autumn Statement to help deliver better returns for savers and boost economic growth. This largely focuses on consolidating sub-scale pension funds. Labour’s Shadow Chancellor, Rachel Reeves, said they would go even further.

The Chancellor announced a new Growth Fund run by the British Business Bank to give pension funds access to investment opportunities in the UK’s most promising businesses. This would be particularly beneficial if they did not feel they had their in-house expertise to make venture capital investments. The BIA has called for this over many years as it is a great opportunity for pension funds to invest in the most innovative companies with the confidence that they are investing alongside the government and expert investors.

There will also be a new Venture Capital Fellowship Scheme to nurture the next generation of UK VCs to help manage capital unlocked from pension funds in the future. This will build on the expert and effective community of life science VCs we have already. Originally proposed by the Life Sciences Scale-Up Taskforce, which BIA led with the Office for Life Sciences, a fellowship programme will provide structured support for mid-career level VCs, share best practice and build the community, similar to the successful US Kauffman Fellowship

The Long-term Investment In Technology and Science (LIFTS) competition, launched at Autumn Statement 2022, invited pension funds and venture capital firms to form consortiums and bid for £250 million to unlock new investment from pension funds into innovative tech and science companies. British Business Bank has run the competition. We are aware of some life science VC funds that have submitted applications alongside those focused on other sectors. An announcement on 21 November said £250 million would be allocated but we understand contractual discussions are still ongoing.  

The Bank also received £50 million additional funding for Future Fund: Breakthrough, which invests directly into scaling deep tech and life science companies.  

Supporting spin-outs

The Government has accepted of all the recommendations of the Independent Spin-Out Review and provided £20 million in funding to support proof-of-concept funding for more spin-outs.

The reviews 11 recommendations included increasing entrepreneur training for PhD students, sharing resources and expertise across university technology transfer offices (TTOs) and bring greater consistency to spin-out deal terms. The government has accepted all the recommendations and published a full response.

Life sciences innovation and data

The Autumn Statement committed £10 million to a Manufacturing Centre of Excellence in Oligonucleotides, with an additional £10 million from Scottish Enterprise. To mark the 2028 centenary of the discovery of penicillin, the government is granting £5 million seed funding to help launch the Fleming Centre. A collaboration led by Imperial College London and Imperial College Healthcare NHS Trust, the Centre will support the next generation of world-changing health innovations.

The UK is uniquely placed to harness the power of health data to improve patient outcomes. To help do this, the Government announced a further £51 million for Our Future Health (OFH). Genomics England, along with a consortium of partners, will also launch a world-first Rare Therapies Launch Pad, generating evidence on whether a pathway for new individualised therapeutics could be implemented in the UK for children with ultra-rare disease.

Sir Paul Nurse’s review of the UK’s research, development and innovation (RDI) organisational landscape was also published alongside the Autumn Statement. BIA submitted to the review and we’ll assess its recommendations shortly. 

Regulation and clinical trials

In May 2023, the Government committed £121 million in funding as a first response to Lord O’Shaughnessy’s recommendations on improving the UK’s commercial clinical trial offer. Up to £20 million of this funding will now be used to launch the first Clinical Trial Delivery Accelerator, focused on dementia, to help innovation reach NHS patients faster. The Government’s full response to the review and an implementation plan was published alongside the Autumn Statement.


The government is supporting plans to catalyse the growth sectors, including life sciences, by committing £50 million to deliver a two-year apprenticeships pilot to explore ways to stimulate training in these sectors and address barriers to entry in high-value standards.


More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

More within